Clinical Trials

79 enrolled

Breast

HER-2 Negative Breast Cancer

NCT07293468 2026-04-09

BIIRTH

Phase 2/3 Recruiting

106 enrolled

Carcinoma, Hepatocellular

NCT05769010 2026-04-01

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

150 enrolled

Breast

Breast Neoplasms

NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Phase 2/3 Recruiting

120 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Phase 2/3 Recruiting

120 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04776655 2025-10-02

LIBImAb

Phase 3 Recruiting

280 enrolled

Colorectal Neoplasms

NCT07128251 2025-08-17

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

47 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07070713 2025-07-17

Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

44 enrolled

Metastatic Colorectal Cancer With Left-sided Primary Tumor

NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Phase NA Recruiting

60 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

220 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06788171 2025-01-23

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

35 enrolled

Colorectal Cancer Liver Metastasis

NCT06293014 2024-03-05

TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

224 enrolled

Colorectal Neoplasms

NCT05675033 2023-01-09

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

50 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT05640726 2022-12-07

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

30 enrolled

Rectal Neoplasms

NCT05357417 2022-09-16

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

100 enrolled

Breast

Breast Neoplasms

NCT05314101 2022-08-23

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

25 enrolled

Phase EARLY_PHASE1 Unknown

Colorectal Neoplasms

NCT05411757 2022-06-09

IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer

12 enrolled

Advanced Primary Liver Cancer

NCT03126799 2022-04-06

AvaTa

128 enrolled

Thoracic

EGFR Positive Non-small Cell Lung Cancer

NCT03380689 2021-03-08

SIRB2

Phase 1 Withdrawn

Colorectal Neoplasms

NCT03240549 2017-08-07

Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease

159 enrolled

Thoracic

Non-small Cell Lung Cancer Metastatic

NCT00450203 2016-12-01

ST03

Phase 2/3 Unknown

1,103 enrolled

Oesophagogastric Cancer

NCT01296815 2015-07-27

Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity

Phase 2 Completed

14 enrolled 7 charts

Sarcoma

Sarcoma, Kaposi

NCT01249521 2010-11-30

Vengeance

40 enrolled